Introduction
The global fabry disease treatment market size is anticipated to around USD 3.9 billion by 2026, this market is anticipated to grow with 10.1% CAGR during the forecast time period.
Market Dynamics
Increasing cohort of Fabry infection, expanding adoption of novel treatments, for example, chaperone treatment, and potential endorsement of pipeline drugs including substrate decrease treatments and compound substitution treatments are giving a fillip to the market.
Fabry ailment is an uncommon acquired lysosomal stockpiling issue caused by hereditary transformation that meddles with capacity of alpha galactosidase protein. Fabry illness for the most part has a late beginning with mellow manifestations, because of which a few patients are frequently undiscovered. Standard of consideration for the board of the sickness is catalyst substitution treatment (ERT). Sanofi's Fabrazyme and Shire's Replagal are the main endorsed ERTs in the EU; anyway in the U.S., just Fabrazyme has been affirmed.
Market Insights
Growing base of patients suffering with Fabry illness combined with expanded appropriation of novel treatments, for example, chaperone treatment has helped the market gain energy. Other than this, broad R&D exercises and potential endorsement of promising pipeline products including substrate decrease treatments and compound substitution treatments are anticipated to raise the development of the over the forecast period.
Fabry sickness is an uncommon X-connected lysosomal storage issue with an insufficiency of alpha galactosidase chemical bringing about dynamic organ brokenness. This illness is caused by unusual development of a particular greasy issue called globotriaosylceramide in different tissues of the body including eyes, skin, kidney, gastrointestinal system, central nervous system and heart, brain.
Patients suffering Fabry disease regularly advancement to a phase of serious torment of furthest points, compromised kidney work frequently advancing to full kidney disappointment, early heart issue, stroke, and incapacitating gastrointestinal side effects. In view of the absence of a therapeudic answer for Fabry disease, treatment alternatives for the most part go for the board of inconveniences related with infection movement and giving symptomatic alleviation.
Market Segmentation
Market By Treatment
- Enzyme Replacement Therapy (ERT)
- Chaperone Treatment
- Substrate Reduction Therapy (SRT)
- Others
Market By Geography
- North America
- Europe
- UK
- Germany
- France
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- Rest of Asia-Pacific
- Latin America
- Brazil
- Chile
- Rest of Latin America
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- Rest of MEA
Regional Insights
Asia Pacific presents massive development open doors for pharmaceutical organizations because of expanding human services consumption and improving infrastructure. The locale is probably going to encounter the quickest development during the coming years, trailed by Latin America, essentially because of substantial populaces in rising nations.North America was the most prominent regional market in 2018, trailed by Europe. Higher selection of novel treatments, better social insurance offices, and great repayment arrangements are assuming a crucial job in the development of the market in the region. Inclusion of costly prescriptions, for example, Fabrazyme by health insurance programs and good legislative medicinal services arrangements are likewise inciting medication organizations to build R&D demand in the field of rare diseases.
Market Participants
Few of the main businesses present in the global Fabry Disease Treatment market are Green Cross Pharma Pte Ltd.; Sanofi S.A.; Moderna Therapeutics Inc.; Shire Plc.; Greenovation Biotech Avrobio Inc.; GmbH; Amicus Therapeutics Inc.; Idorsia Pharmaceuticals Ltd.; ISU Abxis Co Ltd.; JCR Pharmaceuticals Co Ltd. and ProtalixBiotherapeutics Inc. Significanttactical initiatives undertaken by global industries include partnerships, acquisitionsand new product launch.
CHAPTER 1. INDUSTRY OVERVIEW
1.1. Definition and Scope
1.1.1. Definition of Fabry Disease Treatment
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Fabry Disease Treatment Market By Treatment
1.2.2.1. Global Fabry Disease Treatment Market Revenue and Growth Rate Comparison By Treatment (2015-2026)
1.2.2.2. Global Fabry Disease Treatment Market Revenue Share By Treatment in 2017
1.2.2.3. Enzyme Replacement Therapy (ERT)
1.2.2.4. Chaperone Treatment
1.2.2.5. Substrate Reduction Therapy (SRT)
1.2.2.6. Others
1.2.3. Fabry Disease Treatment Market by Geography
1.2.3.1. Global Fabry Disease Treatment Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.3.2. North America Fabry Disease Treatment Market Revenue and Growth Rate (2015-2026)
1.2.3.3. Europe Fabry Disease Treatment Market Revenue and Growth Rate (2015-2026)
1.2.3.4. Asia-Pacific Fabry Disease Treatment Market Revenue and Growth Rate (2015-2026)
1.2.3.5. Latin America Fabry Disease Treatment Market Revenue and Growth Rate (2015-2026)
1.2.3.6. Middle East and Africa (MEA) Fabry Disease Treatment Market Revenue and Growth Rate (2015-2026)
CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS
2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players
CHAPTER 3. MANUFACTURING PLANTS ANALYSIS
3.1. Capacity and Commercial Production Date of Global Fabry Disease Treatment Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Fabry Disease Treatment Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Fabry Disease Treatment Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Fabry Disease Treatment Major Manufacturers in 2017
CHAPTER 4. FABRY DISEASE TREATMENT MARKET BY TREATMENT
4.1. Global Fabry Disease Treatment Revenue By Treatment
4.2. Enzyme Replacement Therapy (ERT)
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Chaperone Treatment
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Substrate Reduction Therapy (SRT)
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Others
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 5. NORTH AMERICA FABRY DISEASE TREATMENT MARKET BY COUNTRY
5.1. North America Fabry Disease Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2. North America Fabry Disease Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
5.3. U.S.
5.3.1. U.S. Fabry Disease Treatment Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
5.4. Canada
5.4.1. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
5.5. Mexico
5.5.1. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
5.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
CHAPTER 6. EUROPE FABRY DISEASE TREATMENT MARKET BY COUNTRY
6.1. Europe Fabry Disease Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2. Europe Fabry Disease Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
6.3. UK
6.3.1. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
6.4. Germany
6.4.1. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
6.5. France
6.5.1. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
6.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
6.6. Spain
6.6.1. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
6.6.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
6.7. Rest of Europe
6.7.1. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
6.7.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
CHAPTER 7. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET BY COUNTRY
7.1. Asia-Pacific Fabry Disease Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. Asia-Pacific Fabry Disease Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. China
7.3.1. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.4. Japan
7.4.1. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.5. India
7.5.1. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.6. Australia
7.6.1. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
7.6.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.7. South Korea
7.7.1. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
7.7.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.8. Rest of Asia-Pacific
7.8.1. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
7.8.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
CHAPTER 8. LATIN AMERICA FABRY DISEASE TREATMENT MARKET BY COUNTRY
8.1. Latin America Fabry Disease Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Latin America Fabry Disease Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. Brazil
8.3.1. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.4. Argentina
8.4.1. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.5. Rest of Latin America
8.5.1. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
CHAPTER 9. MIDDLE EAST FABRY DISEASE TREATMENT MARKET BY COUNTRY
9.1. Middle East Fabry Disease Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Middle East Fabry Disease Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. Saudi Arabia
9.3.1. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.4. UAE
9.4.1. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.5. Rest of Middle East
9.5.1. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
CHAPTER 10. AFRICA FABRY DISEASE TREATMENT MARKET BY COUNTRY
10.1. Africa Fabry Disease Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Africa Fabry Disease Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. South Africa
10.3.1. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.4. Egypt
10.4.1. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.5. Rest of Africa
10.5.1. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
CHAPTER 11. COMPANY PROFILE
11.1. Green Cross Pharma Pte Ltd.
11.1.1. Company Snapshot
11.1.2. Overview
11.1.3. Financial Overview
11.1.4. Product Portfolio
11.1.5. Key Developments
11.1.6. Strategies
11.2. Sanofi S.A.
11.2.1. Company Snapshot
11.2.2. Overview
11.2.3. Financial Overview
11.2.4. Product Portfolio
11.2.5. Key Developments
11.2.6. Strategies
11.3. Moderna Therapeutics Inc.
11.3.1. Company Snapshot
11.3.2. Overview
11.3.3. Financial Overview
11.3.4. Product Portfolio
11.3.5. Key Developments
11.3.6. Strategies
11.4. Shire Plc.
11.4.1. Company Snapshot
11.4.2. Overview
11.4.3. Financial Overview
11.4.4. Product Portfolio
11.4.5. Key Developments
11.4.6. Strategies
11.5. Greenovation Biotech Avrobio Inc.; GmbH
11.5.1. Company Snapshot
11.5.2. Overview
11.5.3. Financial Overview
11.5.4. Product Portfolio
11.5.5. Key Developments
11.5.6. Strategies
11.6. Amicus Therapeutics Inc.
11.6.1. Company Snapshot
11.6.2. Overview
11.6.3. Financial Overview
11.6.4. Product Portfolio
11.6.5. Key Developments
11.6.6. Strategies
11.7. Idorsia Pharmaceuticals Ltd.
11.7.1. Company Snapshot
11.7.2. Overview
11.7.3. Financial Overview
11.7.4. Product Portfolio
11.7.5. Key Developments
11.7.6. Strategies
11.8. ISU Abxis Co Ltd.
11.8.1. Company Snapshot
11.8.2. Overview
11.8.3. Financial Overview
11.8.4. Product Portfolio
11.8.5. Key Developments
11.8.6. Strategies
11.9. JCR Pharmaceuticals Co Ltd.
11.9.1. Company Snapshot
11.9.2. Overview
11.9.3. Financial Overview
11.9.4. Product Portfolio
11.9.5. Key Developments
11.9.6. Strategies
11.10. ProtalixBiotherapeutics Inc.
11.10.1. Company Snapshot
11.10.2. Overview
11.10.3. Financial Overview
11.10.4. Product Portfolio
11.10.5. Key Developments
11.10.6. Strategies
11.11. Others
11.11.1. Company Snapshot
11.11.2. Overview
11.11.3. Financial Overview
11.11.4. Product Portfolio
11.11.5. Key Developments
11.11.6. Strategies
CHAPTER 12. RESEARCH APPROACH
12.1. Research Methodology
12.1.1. Initial Data Search
12.1.2. Secondary Research
12.1.3. Primary Research
12.2. Assumptions and Scope
